COVID 2019 vaccine - ImmunityBio
Alternative Names: Ad5-Covid-S/N vaccine; bivalent hAd5 vaccine - ImmunityBio; hAd5 S + N vaccine; hAd5 S+N T cell vaccine; hAd5 T-Cell COVID-19 Vaccine; hAd5-COVID-19; hAd5-S-Fusion+N-ETSD vaccine; SARS-CoV-2 infections vaccine - ImmunityBioLatest Information Update: 28 Apr 2024
At a glance
- Originator ImmunityBio
- Class COVID-19 vaccines; DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in South Africa (SC, Injection)
- 28 Mar 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in USA (PO, Capsule)
- 28 Mar 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in USA (Sublingual)